Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada

Canadian Journal of Neurological Sciences

Volumn 43, Issue 4, 2016, Pages 503-512

  Laforce, Robert ^a,b   Rosa Neto, Pedro ^c   Soucy, Jean Paul ^d,e,f   Rabinovici, Gil D ^g   Dubois, Bruno ^h,i   Gauthier, S ^c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e Dept of Electrical and Computer Engineering   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer's Disease; Amyloid imaging; Atypical Dementia; Biomarkers; Consensus Guidelines; MCI; PET

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CANADIAN; CEREBROSPINAL FLUID; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR AMYLOIDOSIS; BIBLIOGRAPHIC DATABASE; CANADA; DIAGNOSTIC IMAGING; METABOLISM; MULTICENTER STUDY (TOPIC); PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; CANADA; CONSENSUS; DATABASES, BIBLIOGRAPHIC; GUIDELINES AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84975709560     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2015.401     Document Type: Article

References (89)

1. Patterson CJ, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;160:S1-15.
2. Chertkow H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ. 2008;178:316-21.
3. Gauthier S, Patterson C, Chertkow H, et al. 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci. 2012;39:S1-8.
4. Assessing dementia: the Canadian consensus. Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia. Can Med Assoc J. 1991;144:851-3.
5. Dubois B, Feldman H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revisiting the NINCDSADRDA criteria. Lancet Neurol. 2007;6:734-46.
6. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-27.
7. McKhann G, Knopman D, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011;7:263-9.
8. Albert M, DeKosky S, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270 9.
9. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
10. Burhan A, Bartha R, Bocti C, et al. Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5:S4.
11. Soucy J-P, Bartha R, Bocti C, et al. Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5:S3.
12. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19.
13. Jack CR, Jr., Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732-40.
14. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.
15. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261-71.
16. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-72.
17. Keller D. Finally, a big win for a monoclonal in Alzheimer's. AD/PD 2015: International Conference on Alzheimer's and Parkinson's Diseases 2015 [cited 2015, July 31]. Available from: http://www. medscape.com/viewarticle/841856.
18. Clark C, Pontecorvo M, Beach T, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-78.
19. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398-403.
20. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-35.
21. Ossenkoppele R, Prins ND, Pijnenburg YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414-21.
22. Sanchez-Juan P, Ghosh PM, Hagen J, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82:230-8.
23. Rabinovici G, Rosen H, Alkalay A, et al. Amyloid versus FDG PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034-42.
24. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8:389-98.
25. Bensaïdane M, Fortin M, Damasse G, Chenard M, Dionne C. Clinical utility of amyloid imaging in a complex case of corticobasal syndrome presenting with psychiatric symptoms. J Neurol Disord. 2014;2:2.
26. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimers Dis Assoc Disord. 2013;27:4-15.
27. Zannas AS, Doraiswamy PM, Shpanskaya KS, et al. Impact of 18F-florbetapir PET imaging of beta-amyloid neuritic plaque density on clinical decision-making. Neurocase. 2014;20:466-73.
28. Mitsis E, Bender H, Kostakoglu L, et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10.
29. Bensaïdane MR, Beauregard JM, Poulin S, et al. (forthcoming). Clinical utility of amyloid PET Imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016.
30. Pike K, Savage G, Villemagne V, et al. Beta-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837-44.
31. Rowe C, Ellis K, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-83.
32. Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13:997-1005.
33. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-94.
34. Petersen RC. MIld cognitive impairment or questionable dementia? Arch Neurol. 2000;57:643-4.
35. Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between A? load and cognition in cognitively normal older adults. Neurology. 2012;78:232-40.
36. Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379-85.
37. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497-510.
38. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784-91.
39. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32:S20-36.
40. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198-207.
41. Pontecorvo M, Mintun M. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther. 2011;3:11.
42. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557-68.
43. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73:754-60.
44. Ellis KA, Lim YY, Harrington K, et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis. 2013;34:861-71.
45. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388-401.
46. de Souza LC, Corlier F, Habert MO, et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain. 2011;134:2036-43.
47. Laforce R, Buteau J, Paquet N, Verret L, Houde M, Bouchard R. The value of PET in mild cognitive impairment, typical and atypical/ unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Dement. 2010;25:324-32.
48. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615-21.
49. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130:2636-45.
50. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-7.
51. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-73.
52. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid pet positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939-50.
53. Cselényi Z, Jönhagen ME, Forsberg A, et al. Clinical validation of 18F-AZD4694, an amyloid-?-specific PET radioligand. J Nucl Med. 2012;53:415-24.
54. Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated A? plaque neuroimaging PET radioligand. J Neurochem. 2010;114:784-94.
55. Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880-6.
56. Lee JH, Kim SH, Kim GH, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011;77:18-25.
57. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-34.
58. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107-12.
59. Johnson K, Minoshima S, Bohnen N, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9:1-15.
60. Jagust WJ. Amyloid imaging: liberal or conservative? Let the data decide. Arch Neurol. 2011;68:1377-8.
61. Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54: 1011-3.
62. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287-94.
63. Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11:964-74.
64. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
65. Harkins K, Sankar P, Sperling R, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7:26.
66. Laforce R, Rabinovici G. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther. 2011;3:31.
67. Ducharme S, Guiot M-C, Nikelski J, Chertkow H. Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease? JAMA Neurol. 2013;70:912-4.
68. Bohnen N, Djang D, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59-71.
69. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-7.
70. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.
71. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-8.
72. Silverman D, Small G, Chang C, et al. Positron emission tomography in evaluation of dementia-regional brain metabolism and longterm outcome. JAMA. 2001;286:2120-7.
73. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43:253-66.
74. Jack C, Wiste H, Vemuri P, et al. Brain beta-amyloid measure and magnetic resonance imaging atrophy both predict time-toprogression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336-48.
75. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
76. Fagan AM, Head D, Shah AR, et al. Decreased CSF A?42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176-83.
77. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282-9.
78. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74:826-36.
79. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38-48.
80. Mulder C, Verwey NA, van der Flier WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56:248-53.
81. Rosa-Neto P, Hsiung G-Y, Masellis M, on behalf of the CCDTD4 participants. Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimers Res Ther. 2013;5:S8.
82. Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:350-4.
83. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827-35.
84. Borroni B, Malinverno M, Gardoni F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology. 2008;71:1796-803.
85. Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2008;22:47-53.
86. Hu WT, Watts K, Grossman M, et al. Reduced CSF p-tau181 to tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81: 1945-52.
87. Bibl M, Mollenhauer B, Lewczuk P, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord. 2011;31:37-44.
88. Global Biomarker Standardization Consortium. Biomarker Standardization Projects. 2015 [cited 2015, Aug 29]; Available from: http://www.alz.org/research/funding/global-biomarker-projects. asp.
89. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578-86.